BT-001 ESMO 2024
Category: Press release
Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
TG4050
Transgene’s Combined General Meeting of May 15, 2024
General meeting 2024
Transgene provides business and financial update for Q1 2024
Financial update Q1 2024
Availability of of Preparatory Documents for the Combined General Meeting of May 15, 2024
Shareholders’ meeting 2024
Availability of Transgene’s 2023 Universal Registration Document
URD 2023
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
TG4050 AACR 2024
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
appointment Lucie Larguier et Christelle Schwoerer
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
2023 financial results and business update
Transgene Announces Upcoming Investor Meetings
upcoming investor meetings